<DOC>
	<DOCNO>NCT00660387</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority levodopa - carbidopa intestinal gel treatment optimized oral levodopa/carbidopa 12 week .</brief_summary>
	<brief_title>Study Efficacy , Safety Tolerability Levodopa-Carbidopa Intestinal Gel Levodopa-Responsive Parkinson 's Subjects</brief_title>
	<detailed_description>Study S187.3.001 ( NCT00357994 ) Study S187.3.002 ( NCT00660387 ) 2 identically design , Phase 3 , 12-week , randomize , double-blind , double-dummy , parallel-group , multicenter study recruit subject distinct site . These study evaluate efficacy , safety , tolerability levodopa-carbidopa intestinal gel ( LCIG ) treatment levodopa-responsive subject advance PD persistent severe motor fluctuation , despite optimize treatment oral levodopa-carbidopa , concomitant available antiparkinsonian medication . Participants randomize either LCIG active gel + placebo capsule levodopa-carbidopa immediate release ( IR ) active capsule + placebo gel . Both treatment arm receive percutaneous endoscopic gastrostomy jejunal extension ( PEG-J ) procedure gel administration , active LCIG placebo gel . Data 2 study combine analysis . The decision combine study data analysis make enrollment complete study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Idiopathic Parkinson 's disease ( PD ) accord United Kingdom Parkinson 's Disease Society ( UKPDS ) Brain Bank Criteria Levodoparesponsive participant demonstrate identifiable 'on response , ' establish Investigator observation Demonstrate severe motor fluctuation spite individually optimize treatment therapy option indicate Diagnosis unclear suspicion parkinsonian syndrome exist secondary parkinsonism Undergone surgery treatment PD Contraindications levodopa Subjects neurological deficit may interfere study assessment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>levodopa-carbidopa</keyword>
	<keyword>Carbidopa</keyword>
	<keyword>levodopa</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>Duodopa</keyword>
	<keyword>levodopa-carbidopa intestinal gel</keyword>
	<keyword>Severe Motor Fluctuations</keyword>
	<keyword>levodopa/carbidopa suspension</keyword>
	<keyword>DUOPA</keyword>
</DOC>